nach oben

DGNeurologie

Erschienen in:

13.10.2022 | Evozierte Potentiale | CME Zertifizierte Fortbildung

Small-Fiber-Neuropathien

verfasst von: Dr. J. Sachau, Jun.-Prof. Dr. E. Enax-Krumova

Erschienen in: DGNeurologie | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Small-Fiber-Neuropathie (SFN) ist eine Erkrankung des peripheren Nervensystems aufgrund einer isolierten oder vorwiegenden Schädigung dünn myelinisierter Aδ-Fasern und/oder unmyelinisierter C‑Fasern. Für die sichere Diagnose einer SFN ist neben der klinischen Symptomatik mit Schmerzen und Sensibilitätsstörungen, typischerweise mit distal betonter Ausbreitung, der apparative Nachweis einer Rarefizierung oder einer Funktionsstörung der dünn myelinisierten Aδ-Fasern und/oder der unmyelinisierten C‑Fasern gefordert. Im vorliegenden Beitrag wird eine Übersicht über die diagnostischen Verfahren zum Nachweis einer SFN sowie über mögliche Ursachen und Behandlungsoptionen gegeben.

Bitzi LM, Lehnick D, Wilder-Smith EP (2021) Small fiber neuropathy: Swiss cohort characterization. Muscle Nerve 64:293–300. https://doi.org/10.1002/mus.27340CrossRefPubMedPubMedCentral

Peters MJH, Bakkers M, Merkies ISJ et al (2013) Incidence and prevalence of small-fiber neuropathy: a survey in the Netherlands. Neurology 81:1356–1360. https://doi.org/10.1212/WNL.0b013e3182a8236eCrossRefPubMed

Gemignani F (2022) Epidemiology and features of non-length-dependent small fiber neuropathy. Muscle Nerve 65:E1. https://doi.org/10.1002/mus.27433CrossRefPubMed

Gemignani F, Bellanova MF, Saccani E, Pavesi G (2022) Non-length-dependent small fiber neuropathy: not a matter of stockings and gloves. Muscle Nerve 65:10–28. https://doi.org/10.1002/mus.27379CrossRefPubMed

Levine TD (2018) Small fiber neuropathy: disease classification beyond pain and burning. J Cent Nerv Syst Dis 10:1179573518771703. https://doi.org/10.1177/1179573518771703CrossRefPubMedPubMedCentral

Devigili G, Tugnoli V, Penza P et al (2008) The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 131:1912–1925. https://doi.org/10.1093/brain/awn093CrossRefPubMedPubMedCentral

Tesfaye S, Boulton AJM, Dyck PJ et al (2010) Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33:2285–2293. https://doi.org/10.2337/dc10-1303CrossRefPubMedPubMedCentral

Terkelsen AJ, Karlsson P, Lauria G et al (2017) The diagnostic challenge of small fibre neuropathy: clinical presentations, evaluations, and causes. Lancet Neurol 16:934–944. https://doi.org/10.1016/S1474-4422(17)30329-0CrossRefPubMed

Haroutounian S, Todorovic MS, Leinders M et al (2020) Diagnostic criteria for idiopathic small fiber neuropathy: a systematic review. Muscle Nerve. https://doi.org/10.1002/mus.27070CrossRefPubMed

10.

Itani M, Gylfadottir SS, Krøigård T et al (2020) Small and large fiber sensory polyneuropathy in type 2 diabetes: influence of diagnostic criteria on neuropathy subtypes. J Peripher Nerv Syst. https://doi.org/10.1111/jns.12424CrossRefPubMed

11.

Dohrn MF, Lampert A, Üçeyler N, Kurth I (2019) Neuropathic pain syndromes and channelopathies. Internist (Berl) 60:90–97. https://doi.org/10.1007/s00108-018-0535-xCrossRef

12.

Verdugo RJ, Matamala JM, Inui K et al (2022) Review of techniques useful for the assessment of sensory small fiber neuropathies: report from an IFCN expert group. Clin Neurophysiol 136:13–38. https://doi.org/10.1016/j.clinph.2022.01.002CrossRefPubMed

13.

Schlereth T (2020) Guideline “diagnosis and non interventional therapy of neuropathic pain” of the German society of neurology (deutsche Gesellschaft für Neurologie). Neurol Res Pract 2:16. https://doi.org/10.1186/s42466-020-00063-3CrossRefPubMedPubMedCentral

14.

Backonja MM, Attal N, Baron R et al (2013) Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. Pain 154:1807–1819. https://doi.org/10.1016/j.pain.2013.05.047CrossRefPubMed

15.

Rolke R, Baron R, Maier C et al (2006) Quantitative sensory testing in the German research network on neuropathic pain (DFNS): standardized protocol and reference values. Pain 123:231–243. https://doi.org/10.1016/j.pain.2006.01.041CrossRefPubMed

16.

Magerl W, Krumova EK, Baron R et al (2010) Reference data for quantitative sensory testing (QST): refined stratification for age and a novel method for statistical comparison of group data. Pain 151:598–605. https://doi.org/10.1016/j.pain.2010.07.026CrossRefPubMed

17.

Pfau DB, Krumova EK, Treede R-D et al (2014) Quantitative sensory testing in the German research network on neuropathic pain (DFNS): reference data for the trunk and application in patients with chronic postherpetic neuralgia. Pain 155:1002–1015. https://doi.org/10.1016/j.pain.2014.02.004CrossRefPubMed

18.

Koulouris AE, Edwards RR, Dorado K et al (2020) Reliability and validity of the Boston bedside quantitative sensory testing battery for neuropathic pain. Pain Med 21:2336–2347. https://doi.org/10.1093/pm/pnaa192CrossRefPubMedPubMedCentral

19.

Reimer M, Forstenpointner J, Hartmann A et al (2020) Sensory bedside testing: a simple stratification approach for sensory phenotyping. Pain Rep 5:e820. https://doi.org/10.1097/PR9.0000000000000820CrossRefPubMedPubMedCentral

20.

Wasan AD, Alter BJ, Edwards RR et al (2020) Test-retest and inter-examiner reliability of a novel bedside quantitative sensory testing battery in postherpetic neuralgia patients. J Pain 21:858–868. https://doi.org/10.1016/j.jpain.2019.11.013CrossRefPubMed

21.

Zhu GC, Böttger K, Slater H et al (2019) Concurrent validity of a low-cost and time-efficient clinical sensory test battery to evaluate somatosensory dysfunction. Eur J Pain 23:1826–1838. https://doi.org/10.1002/ejp.1456CrossRefPubMedPubMedCentral

22.

Wang L, Hilliges M, Jernberg T et al (1990) Protein gene product 9.5-immunoreactive nerve fibres and cells in human skin. Cell Tissue Res 261:25–33. https://doi.org/10.1007/BF00329435CrossRefPubMed

23.

Lauria G, Bakkers M, Schmitz C et al (2010) Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. J Peripher Nerv Syst 15:202–207. https://doi.org/10.1111/j.1529-8027.2010.00271.xCrossRefPubMed

24.

Provitera V, Gibbons CH, Wendelschafer-Crabb G et al (2016) A multi-center, multinational age- and gender-adjusted normative dataset for immunofluorescent intraepidermal nerve fiber density at the distal leg. Eur J Neurol 23:333–338. https://doi.org/10.1111/ene.12842CrossRefPubMed

25.

Provitera V, Gibbons CH, Wendelschafer-Crabb G et al (2018) The role of skin biopsy in differentiating small-fiber neuropathy from ganglionopathy. Eur J Neurol 25:848–853. https://doi.org/10.1111/ene.13608CrossRefPubMed

26.

Lauria G, Hsieh ST, Johansson O et al (2010) European federation of neurological societies/peripheral nerve society guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European federation of neurological societies and the peripheral nerve society. Eur J Neurol 17:903–912. https://doi.org/10.1111/j.1468-1331.2010.03023.xCrossRefPubMed

27.

Chen X, Graham J, Dabbah MA et al (2015) Small nerve fiber quantification in the diagnosis of diabetic sensorimotor polyneuropathy: comparing corneal confocal microscopy with intraepidermal nerve fiber density. Diabetes Care 38:1138–1144. https://doi.org/10.2337/dc14-2422CrossRefPubMedPubMedCentral

28.

Loavenbruck A, Wendelschaefer-Crabbe G, Sandroni P, Kennedy WR (2014) Quantification of sweat gland volume and innervation in neuropathy: correlation with thermoregulatory sweat testing. Muscle Nerve 50:528–534. https://doi.org/10.1002/mus.24185CrossRefPubMed

29.

Penza P, Lombardi R, Camozzi F et al (2009) Painful neuropathy in subclinical hypothyroidism: clinical and neuropathological recovery after hormone replacement therapy. Neurol Sci 30:149–151. https://doi.org/10.1007/s10072-009-0026-xCrossRefPubMed

30.

Nodera H, Barbano RL, Henderson D, Herrmann DN (2003) Epidermal reinnervation concomitant with symptomatic improvement in a sensory neuropathy. Muscle Nerve 27:507–509. https://doi.org/10.1002/mus.10336CrossRefPubMed

31.

Singleton JR, Marcus RL, Jackson JE et al (2014) Exercise increases cutaneous nerve density in diabetic patients without neuropathy. Ann Clin Transl Neurol 1:844–849. https://doi.org/10.1002/acn3.125CrossRefPubMedPubMedCentral

32.

Üçeyler N (2016) Small fiber pathology—a culprit for many painful disorders? Pain 157(1):S60–S66. https://doi.org/10.1097/j.pain.0000000000000411CrossRefPubMed

33.

Merkies ISJ, Faber CG, Lauria G (2015) Advances in diagnostics and outcome measures in peripheral neuropathies. Neurosci Lett 596:3–13. https://doi.org/10.1016/j.neulet.2015.02.038CrossRefPubMed

34.

Valeriani M, Pazzaglia C, Cruccu G, Truini A (2012) Clinical usefulness of laser evoked potentials. Neurophysiol Clin 42:345–353. https://doi.org/10.1016/j.neucli.2012.05.002CrossRefPubMed

35.

Siedler G, Sommer C, Üçeyler N (2020) Pain-related evoked potentials in patients with large, mixed, and small fiber neuropathy. Clin Neurophysiol 131:635–641. https://doi.org/10.1016/j.clinph.2019.12.006CrossRefPubMed

36.

Hüllemann P, Nerdal A, Sendel M et al (2019) Cold-evoked potentials versus contact heat-evoked potentials-methodological considerations and clinical application. Eur J Pain 23:1209–1220. https://doi.org/10.1002/ejp.1389CrossRefPubMed

37.

Müller LJ, Marfurt CF, Kruse F, Tervo TMT (2003) Corneal nerves: structure, contents and function. Exp Eye Res 76:521–542. https://doi.org/10.1016/s0014-4835(03)00050-2CrossRefPubMed

38.

Cruzat A, Qazi Y, Hamrah P (2017) In vivo confocal microscopy of corneal nerves in health and disease. Ocul Surf 15:15–47. https://doi.org/10.1016/j.jtos.2016.09.004CrossRefPubMed

39.

Jiang M-S, Yuan Y, Gu Z-X, Zhuang S-L (2016) Corneal confocal microscopy for assessment of diabetic peripheral neuropathy: a meta-analysis. Br J Ophthalmol 100:9–14. https://doi.org/10.1136/bjophthalmol-2014-306038CrossRefPubMed

40.

Perkins BA, Lovblom LE, Bril V et al (2018) Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study. Diabetologia 61:1856–1861. https://doi.org/10.1007/s00125-018-4653-8CrossRefPubMedPubMedCentral

41.

Adams D, Koike H, Slama M, Coelho T (2019) Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol 15:387–404. https://doi.org/10.1038/s41582-019-0210-4CrossRefPubMed

42.

Weidner C, Klede M, Rukwied R et al (2000) Acute effects of substance P and calcitonin gene-related peptide in human skin—a microdialysis study. J Invest Dermatol 115:1015–1020. https://doi.org/10.1046/j.1523-1747.2000.00142.xCrossRefPubMed

43.

Namer B, Pfeffer S, Handwerker HO et al (2013) Axon reflex flare and quantitative sudomotor axon reflex contribute in the diagnosis of small fiber neuropathy. Muscle Nerve 47:357–363. https://doi.org/10.1002/mus.23543CrossRefPubMed

44.

Buchmann SJ, Penzlin AI, Kubasch ML et al (2019) Assessment of sudomotor function. Clin Auton Res 29:41–53. https://doi.org/10.1007/s10286-018-0530-2CrossRefPubMed

45.

Finsterer J, Scorza FA (2022) Small fiber neuropathy. Acta Neuro Scandinavica 145:493–503. https://doi.org/10.1111/ane.13591CrossRef

46.

Gibbons CH, Freeman R (2015) Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain 138:43–52. https://doi.org/10.1093/brain/awu307CrossRefPubMed

47.

Khan S, Zhou L (2012) Characterization of non-length-dependent small-fiber sensory neuropathy. Muscle Nerve 45:86–91. https://doi.org/10.1002/mus.22255CrossRefPubMed

48.

de Greef BTA, Hoeijmakers JGJ, Gorissen-Brouwers CML et al (2018) Associated conditions in small fiber neuropathy—a large cohort study and review of the literature. Eur J Neurol 25:348–355. https://doi.org/10.1111/ene.13508CrossRefPubMed

49.

Freeman R, Gewandter JS, Faber CG et al (2020) Idiopathic distal sensory polyneuropathy: ACTTION diagnostic criteria. Neurology 95:1005–1014. https://doi.org/10.1212/WNL.0000000000010988CrossRefPubMedPubMedCentral

50.

Odozor CU, Kannampallil T, Ben Abdallah A et al (2022) Post-acute sensory neurological sequelae in patients with severe acute respiratory syndrome coronavirus 2 infection: the COVID-PN observational cohort study. Pain. https://doi.org/10.1097/j.pain.0000000000002639CrossRefPubMed

51.

Abrams RMC, Simpson DM, Navis A et al (2022) Small fiber neuropathy associated with SARS-CoV-2 infection. Muscle Nerve 65:440–443. https://doi.org/10.1002/mus.27458CrossRefPubMed

52.

Novak P, Mukerji SS, Alabsi HS et al (2022) Multisystem involvement in post-acute sequelae of Coronavirus disease 19. Ann Neurol 91:367–379. https://doi.org/10.1002/ana.26286CrossRefPubMedPubMedCentral

53.

Oaklander AL, Mills AJ, Kelley M et al (2022) Peripheral neuropathy evaluations of patients with prolonged long COVID. Neurol Neuroimmunol Neuroinflamm 9:e1146. https://doi.org/10.1212/NXI.0000000000001146CrossRefPubMedPubMedCentral

54.

Sopacua M, Hoeijmakers JGJ, Merkies ISJ et al (2019) Small-fiber neuropathy: expanding the clinical pain universe. J Peripher Nerv Syst 24:19–33. https://doi.org/10.1111/jns.12298CrossRefPubMed

55.

Dib-Hajj SD, Geha P, Waxman SG (2017) Sodium channels in pain disorders: pathophysiology and prospects for treatment. Pain 158(1):S97–S107. https://doi.org/10.1097/j.pain.0000000000000854CrossRefPubMedPubMedCentral

56.

McDonnell A, Schulman B, Ali Z et al (2016) Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile. Brain 139:1052–1065. https://doi.org/10.1093/brain/aww007CrossRefPubMed

57.

Mantyh WG, Dyck PJB, Dyck PJ et al (2017) Epidermal nerve fiber quantification in patients with erythromelalgia. JAMA Dermatol 153:162–167. https://doi.org/10.1001/jamadermatol.2016.4404CrossRefPubMed

58.

Eijkenboom I, Sopacua M, Hoeijmakers JGJ et al (2019) Yield of peripheral sodium channels gene screening in pure small fibre neuropathy. J Neurol Neurosurg Psychiatry 90:342–352. https://doi.org/10.1136/jnnp-2018-319042CrossRefPubMed

59.

Waxman SG, Merkies ISJ, Gerrits MM et al (2014) Sodium channel genes in pain-related disorders: phenotype-genotype associations and recommendations for clinical use. Lancet Neurol 13:1152–1160. https://doi.org/10.1016/S1474-4422(14)70150-4CrossRefPubMed

60.

Conceição I, González-Duarte A, Obici L et al (2016) “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 21:5–9. https://doi.org/10.1111/jns.12153CrossRefPubMedPubMedCentral

61.

Üçeyler N, Ganendiran S, Kramer D, Sommer C (2014) Characterization of pain in fabry disease. Clin J Pain 30:915–920. https://doi.org/10.1097/AJP.0000000000000041CrossRefPubMed

62.

Biegstraaten M, Hollak CEM, Bakkers M et al (2012) Small fiber neuropathy in Fabry disease. Mol Genet Metab 106:135–141. https://doi.org/10.1016/j.ymgme.2012.03.010CrossRefPubMed

63.

de Greef BTA, Hoeijmakers JGJ, Wolters EE et al (2016) No Fabry disease in patients presenting with isolated small fiber neuropathy. PLoS ONE 11:e148316. https://doi.org/10.1371/journal.pone.0148316CrossRefPubMedPubMedCentral

64.

Ghasemi M, Rajabally YA (2020) Small fiber neuropathy in unexpected clinical settings: a review. Muscle Nerve 62:167–175. https://doi.org/10.1002/mus.26808CrossRefPubMed

65.

Enax-Krumova EK, Dahlhaus I, Görlach J et al (2022) Small fiber involvement is independent from clinical pain in late-onset Pompe disease. Orphanet J Rare Dis 17:177. https://doi.org/10.1186/s13023-022-02327-4CrossRefPubMedPubMedCentral

66.

Gaillet A, Champion K, Lefaucheur J-P et al (2019) Intravenous immunoglobulin efficacy for primary Sjögren’s syndrome associated small fiber neuropathy. Autoimmun Rev 18:102387. https://doi.org/10.1016/j.autrev.2019.102387CrossRefPubMed

67.

Pereira PR, Viala K, Maisonobe T et al (2016) Sjögren sensory neuronopathy (Sjögren ganglionopathy): long-term outcome and treatment response in a series of 13 cases. Medicine 95:e3632. https://doi.org/10.1097/MD.0000000000003632CrossRefPubMedPubMedCentral

68.

Tavee JO, Karwa K, Ahmed Z et al (2017) Sarcoidosis-associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment. Respir Med 126:135–138. https://doi.org/10.1016/j.rmed.2017.03.011CrossRefPubMed

69.

Geerts M, de Greef BTA, Sopacua M et al (2021) Intravenous immunoglobulin therapy in patients with painful idiopathic small fiber neuropathy. Neurology. https://doi.org/10.1212/WNL.0000000000011919CrossRefPubMedPubMedCentral

70.

Barroso FA, Judge DP, Ebede B et al (2017) Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid 24:194–204. https://doi.org/10.1080/13506129.2017.1357545CrossRefPubMed

71.

Adams D, Gonzalez-Duarte A, O’Riordan WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11–21. https://doi.org/10.1056/NEJMoa1716153CrossRefPubMed

72.

Benson MD, Waddington-Cruz M, Berk JL et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379:22–31. https://doi.org/10.1056/NEJMoa1716793CrossRefPubMed

73.

Schiffmann R, Floeter MK, Dambrosia JM et al (2003) Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 28:703–710. https://doi.org/10.1002/mus.10497CrossRefPubMed

74.

Schiffmann R, Hauer P, Freeman B et al (2006) Enzyme replacement therapy and intraepidermal innervation density in Fabry disease. Muscle Nerve 34:53–56. https://doi.org/10.1002/mus.20550CrossRefPubMed

75.

Germain DP, Hughes DA, Nicholls K et al (2016) Treatment of Fabry’s disease with the pharmacologic chaperone migalastat. N Engl J Med 375:545–555. https://doi.org/10.1056/NEJMoa1510198CrossRefPubMed

76.

de Greef BTA, Hoeijmakers JGJ, Geerts M et al (2019) Lacosamide in patients with Nav1.7 mutations-related small fibre neuropathy: a randomized controlled trial. Brain 142:263–275. https://doi.org/10.1093/brain/awy329CrossRefPubMed

77.

Labau JIR, Estacion M, Tanaka BS et al (2020) Differential effect of lacosamide on Nav1.7 variants from responsive and non-responsive patients with small fibre neuropathy. Brain 143:771–782. https://doi.org/10.1093/brain/awaa016CrossRefPubMedPubMedCentral

78.

Heuß D. et al. (2019) Diagnostik bei Polyneuropathien, S1-Leitlinie. Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. https://www.dgn.org/leitlinien. Zugegriffen: 15. Aug.2022

Titel: Small-Fiber-Neuropathien
verfasst von: Dr. J. Sachau
Jun.-Prof. Dr. E. Enax-Krumova
Publikationsdatum: 13.10.2022
Verlag: Springer Medizin
Schlagwörter: Evozierte Potentiale
Evozierte Potentiale
Small-Fiber-Neuropathie
Amyloidosen
Erschienen in: DGNeurologie / Ausgabe 6/2022
Print ISSN: 2524-3446
Elektronische ISSN: 2524-3454
DOI: https://doi.org/10.1007/s42451-022-00488-x

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Small-Fiber-Neuropathien

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2022

Kopfschmerzen und atraumatische Subduralblutung – was war die Ursache?

Plötzlich Kribbeln, Reflexverlust und Gangstörungen

Umwandlung von diffusionsgestörtem Hirngewebe zu fokalen Läsionen in Abwesenheit von kontrastmittelanreichernden Läsionen bei der Multiplen Sklerose

Aktuelle Empfehlungen zur Therapie der Vasospasmen bei Subarachnoidalblutung

Magazin

Mitteilungen der Deutschen Gesellschaft für Neurologie

Neu in den Fachgebieten Neurologie und Psychiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

ADHS-Medikation erhöht das kardiovaskuläre Risiko